Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nebivolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nebivolol SCHEMBL866435 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL18255259 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL13762675 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL20007010 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL12375910 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL7919700 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL8511892 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL3909519 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL8503436 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL3791946 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11177 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| US-12576026-B2 | Formulations of nebivolol | EXTROVIS AG (CH) | 2026-03-17 | — | — | US | claimed |
| US-12569434-B2 | Formulations of Nebivolol | EXTROVIS AG (CH) | 2026-03-10 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| WO-1999027990-A2 | STEREOSPECIFIC DELIVERY OF A DRUG USING ELECTROTRANSPORT | ALZA CORPORATION (US) | 1999-06-10 | — | — | WO | claimed |
| US-5874461-A | TREATMENT OF DEGENERATIVE DISEASES OF VASCULAR AND NERVOUS SYSTEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-02-23 | — | — | US | claimed |
| US-5759580-A | HYPOTENSIVE AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1998-06-02 | — | — | US | claimed |
| CN-1171739-A | Use of nebivolol as anti-atherogenic | JANSSEN PHARMACEUTICA NV (BE) | 1998-01-28 | — | — | CN | claimed |
| EP-0801564-A1 | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-22 | — | — | EP | claimed |
| CN-1140991-A | Compositions containing micronized nebivolol | JANSSEN PHARMACEUTICA NV (BE) | 1997-01-22 | — | — | CN | claimed |
| EP-0744946-A1 | COMPOSITIONS CONTAINING MICRONIZED NEBIVOLOL | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-12-04 | — | — | EP | claimed |
| WO-1996019987-A1 | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-07-04 | — | — | WO | claimed |
| WO-1995022325-A1 | COMPOSITIONS CONTAINING MICRONIZED NEBIVOLOL | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-08-24 | — | — | WO | claimed |